Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind Randomized Study of Ceftobiprole Medocaril vs Linezolid plus Ceftazidime in Nosocomial Pneumonia
2005-004174-24Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftobiprole medocaril in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Clinical cure rate at test-of-cure (TOC) visit. Started Jul 2006; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on 2005-004174-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004174-24.